- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | APTAHEM: Newsletter December 2025 | 1 | Cision News | ||
| 05.12.25 | Aptahem receives patent protection in China for patent family 2 | 2 | Cision News | ||
| APTAHEM Aktie jetzt für 0€ handeln | |||||
| 30.10.25 | Aptahem's webinar "Strategic Direction and Planned US Listing" now available | 2 | Cision News | ||
| 22.10.25 | Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing | 2 | Cision News | ||
| 21.10.25 | APTAHEM: Newsletter October 2025 | 1 | Cision News | ||
| 03.10.25 | Spotlight Stock Market: Market Notice 186/25 - Last day of trading in Aptahem AB's BTA | 1 | Cision News | ||
| 25.09.25 | Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue | 1 | Cision News | ||
| 23.09.25 | Aptahem receives Notice of Allowance in China for patent family 2 | 2 | Cision News | ||
| 19.09.25 | Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation | 1 | Cision News | ||
| 02.09.25 | Spotlight Stock Market: Market Notice 164/25 - Information regarding the rights issue from Aptahem AB | 1 | Cision News | ||
| 27.08.25 | Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review | 1 | Cision News | ||
| 27.08.25 | APTAHEM: Newsletter No 2, August 2025 | 1 | Cision News | ||
| 26.08.25 | Aptahem announces Strategic Direction for U.S. Listing to Enable Phase 2 Study and build portfolio assets value | 1 | Cision News | ||
| 20.08.25 | Aptahem files provisional patent application in USA for new indications for Apta-1 | 1 | Cision News | ||
| 13.08.25 | Aptahem Applies to FDA PreCheck Program - Strategic Step Toward Faster, Higher-Quality Drug Manufacturing | 1 | Cision News |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,475 | -0,84 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,82 | +0,14 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 73,21 | 0,00 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| RECURSION PHARMACEUTICALS | 3,565 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 305,95 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 16,550 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,82 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| ERASCA | 11,885 | +5,74 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| LIMINATUS PHARMA | 2,030 | 0,00 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,94 | 0,00 % | Arcellx reports D-Domain binder shows no tonic signaling in CAR T therapy | ||
| SUMMIT THERAPEUTICS | 13,860 | 0,00 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ALUMIS | 26,340 | 0,00 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BIONTECH | 89,80 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| IMMUNOVANT | 24,060 | -4,33 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| CG ONCOLOGY | 49,210 | 0,00 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen |
APTAHEM AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,005 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAHEM AB finden Sie auf Wallstreet Online.